Equity Overview
Price & Market Data
Price: $0.0419
Daily Change: -$0.00565 / 13.50%
Range: $0.0419 - $0.0437
Market Cap: $6,119,879
Volume: 5,350
Performance Metrics
1 Week: -0.21%
1 Month: 10.41%
3 Months: -44.18%
6 Months: -40.63%
1 Year: -20.83%
YTD: -90.50%
Details
Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. The company's preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series for the treatment of PARP resistant adult and childhood cancers; and kt-4000, a DNA-damaging DDR inhibitors. It has a research collaboration with Variational AI Inc. to identify and develop novel small-molecule therapies against DNA-damage response (DDR) targets for the treatment of cancer. Rakovina Therapeutics Inc. was formerly known as Vincero Capital Corp. The company is headquartered in Vancouver, Canada.